期刊文献+

美沙酮维持治疗疗效相关的分子遗传学研究进展

暂未订购
导出
摘要 美沙酮维持治疗(methadone maintenance treatment,MMT)是目前国内外治疗阿片类物质依赖的一种有效方法。然而,在临床应用中,MMT的疗效反应与剂量都存在较大的个体差异。有研究显示,若以是否继续MMT和使用非法阿片类物质作为MMT的疗效评估指标,那么有30-80%的患者治疗效果不佳[1]。研究显示,MMT疗效主要受个体遗传因素(如代谢酶的遗传多态性与美沙酮的药代动力学)、患者临床特征及药物因素如药物剂量等影响[2-5]。目前,关于MMT疗效和不良反应的药物基因组学研究主要集中在美沙酮代谢、作用受体及单胺类神经递质相关的基因。本文对近年来美沙酮维持治疗的药物基因组学研究进展进行综述,期望对指导MMT的个体化治疗提供一些启发。
出处 《中国药物依赖性杂志》 CAS CSCD 2013年第1期1-3,10,共4页 Chinese Journal of Drug Dependence
基金 国家自然科学基金(30971048) 十二五科技支撑计划(2012BAI01B07) 上海市卫生系统新百人计划(XBR2011015)
  • 相关文献

参考文献23

  • 1United States General Accounting Office. Methadone maintenance: some treatment programs are not effective;greater Federal oversights needed[ R]. HRD - 90 - 104, 1990.
  • 2Cacciola JS, Alterman AI, Rutherford M J, et al. The relationship of psychiatric comorbidity to treatment outcomes in methadone maintained patients[J]. Drug Alcohol Depend, 2001, 61:271 -280.
  • 3Elkader AK, Brands B, Dunn E, et al. Major depressive disorder and patient satisfaction in relation to methadone pharmacokineties and pharmacodynamies in stabilized methadone maintenance patients[ J]. J Clin Psychopharmacol, 2009, 29:77 -81.
  • 4Epstein DH, Schmittner J, Umbricht A, et al. Promoting abstinence from cocaine and heroin with a methadone dose increase and a novel contingency[J]. Drug Alcohol Depend, 2009, 101:92 -100.
  • 5Farre M, Mas A, Torrens M, et al. Retention rate and illicit opioid use during methadone maintenance interventions: a meta - analysis[J]. Drug Alcohol Depend, 2002, 65:283-290.
  • 6Crettol S, Deglon JJ, Besson J, et al. ABCB1 and eytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment[J]. Clin Pharmacol Ther, 2006, 80:668 -681.
  • 7Li Y, Kantelip JP, Gerrltsen - van Sehieveen P, et al. Inter - individual variability of methadone response : impact of genetic polymorphism[J]. Mol Diagn Ther, 2008, 12: 109- 124.
  • 8Fonseca F, de la Torte R, Diaz L, et al. Contribution of Cytoehrome P450 and ABCB1 genetic variability on methadone pharmacokinetics, dose requirements and response [ J ]. PLoS ONE, 2011, 6 (5) : e19527.
  • 9Crettol S, Deglon JJ, Besson J, et al. Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment[ J]. Clin Pharmacol Ther, 2005, 78 : 593 - 604.
  • 10Eap CB, Crettol S, Rougier JS, et al. Stereoselective block of hERG channel by (S) -methadone and QT interval prolongation in CYP2B6 slow metabolizers[ J]. Clin Pharmacol Ther, 2007, 81 : 719 -728.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部